--- title: "Oramed Pharmaceuticals Inc. Declares Dividend of $0.25 (NASDAQ:ORMP)" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/271984327.md" description: "Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has declared a dividend of $0.25 per share, payable on January 26th to stockholders of record as of January 16th. The ex-dividend date is also January 16th. The company's stock recently traded at $3.48, with a market cap of $138.31 million and a price-to-earnings ratio of 2.76. Oramed focuses on developing oral drug delivery systems, particularly for diabetes management, with its lead candidate, ORMD-0801, currently in Phase 3 trials." datetime: "2026-01-08T21:13:37.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/271984327.md) - [en](https://longbridge.com/en/news/271984327.md) - [zh-HK](https://longbridge.com/zh-HK/news/271984327.md) --- > 支持的语言: [English](https://longbridge.com/en/news/271984327.md) | [繁體中文](https://longbridge.com/zh-HK/news/271984327.md) # Oramed Pharmaceuticals Inc. Declares Dividend of $0.25 (NASDAQ:ORMP) **Oramed Pharmaceuticals Inc.** (NASDAQ:ORMP - Get Free Report) declared a dividend on Wednesday, January 7th. Stockholders of record on Friday, January 16th will be given a dividend of 0.25 per share by the biotechnology company on Monday, January 26th. The ex-dividend date is Friday, January 16th. Get **Oramed Pharmaceuticals** alerts: ## Oramed Pharmaceuticals Stock Performance NASDAQ:ORMP traded up $0.21 during trading hours on Thursday, hitting $3.48. The stock had a trading volume of 311,721 shares, compared to its average volume of 193,109. The business's 50 day moving average is $2.72 and its 200-day moving average is $2.41. The company has a market cap of $138.31 million, a price-to-earnings ratio of 2.76 and a beta of 1.19. Oramed Pharmaceuticals has a one year low of $1.82 and a one year high of $3.50. ## About Oramed Pharmaceuticals (Get Free Report) Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed's platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery. The company's lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials. ## Recommended Stories - Five stocks we like better than Oramed Pharmaceuticals - A month before the crash - How a Family Trust May Be Able To Help Preserve Your Wealth - Market Panic: Trump Just Dropped a Bomb on Your Stocks - YDES Could Be 2026's Biotech Breakthrough - 1 Hour Once A Day _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Oramed Pharmaceuticals Right Now? Before you consider Oramed Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list. While Oramed Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ## 相关资讯与研究 - [Lexaria Launches New Human Trial to Advance Oral GLP-1 Drug Delivery Platform](https://longbridge.com/zh-CN/news/281413171.md) - [05:00 ETFolly Launches First Pill-Strength Hair Health Gummy](https://longbridge.com/zh-CN/news/281494030.md) - [05:00 ETFolly bringt das erste Gummibonbon für gesundes Haar mit der Wirksamkeit einer Tablette auf den Markt](https://longbridge.com/zh-CN/news/281494430.md) - [Emirates Drug Establishment approves oral obesity treatment, marking shift away from injections](https://longbridge.com/zh-CN/news/281640094.md) - [Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call](https://longbridge.com/zh-CN/news/281187029.md)